dmc

John has over thirty years of experience in developing in vivo models of CNS diseases and evaluating novel strategies for their treatment. Disorders targeted include Alzheimer’s disease, Parkinson’s disease, schizophrenia, drug abuse, and exposure to environmental endocrine disruptors in studies that have involved biochemical, neurochemical, immunohistochemical, ultrastructural and behavioral endpoints. John received his PhD and postdoctoral training at University of London, England, before being recruited to the faculty at Yale University, and joining the Virscio team.